MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Biogen Inc

Fechado

SetorSaúde

125.05 -2.84

Visão Geral

Variação de preço das ações

24h

Atual

Mín

124.47

Máximo

129.26

Indicadores-chave

By Trading Economics

Rendimento

-26M

241M

Vendas

-24M

2.4B

P/E

Médio do Setor

13.153

39.857

EPS

3.02

Margem de lucro

9.893

Funcionários

7,605

EBITDA

19M

554M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+29.46% upside

Dividendos

By Dow Jones

Próximos Ganhos

31 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-915M

20B

Abertura anterior

127.89

Fecho anterior

125.05

Sentimento de Notícias

By Acuity

20%

80%

37 / 376 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

Biogen Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de set. de 2024, 11:00 UTC

Principais Notícias

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

Comparação entre Pares

Variação de preço

Biogen Inc Previsão

Preço-alvo

By TipRanks

29.46% parte superior

Previsão para 12 meses

Média 166.6 USD  29.46%

Máximo 255 USD

Mínimo 115 USD

Com base em 26 analistas de Wall Street que oferecem metas de preço de 12 meses para Biogen Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

26 ratings

12

Comprar

14

Manter

0

Vender

Pontuação Técnica

By Trading Central

118.15 / 121.17Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

37 / 376 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.